Registration link: https://www.eventbrite.com/e/1021029977147?aff=oddtdtcreator Date: Wednesday, Oct 2nd, 2024; 11:00 am PST, or 2:00 pm EST Webinar Highlights: Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating […]
Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]
CCR8, as a novel immune checkpoint in tumor microenvironment, was hotly discussed during 2022 AACR conference. Since then, numerous prestigious pharmaceutical corporations have shifted their attention to CCR8, previously almost unknown. You may wonder why CCR8 gave rise to so strong interest of pharmaceutical industry. Just follow us to have a quick review of CCR8, […]
We provide gene editing techniques such as CRISPR/Cas9, transgenic approaches, or gene knockout strategies.
Researchers can request specific modifications to evaluate phenotypic changes, drug responses, or genetic interactions, facilitating the advancement of biomedical research and therapeutic developments.
Please fill in the order form and we will contact you within 2 working days.
